New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...

If it weren’t for the Interventional Pulmonology team at Geisinger Medical Center and the endobronchial valve procedure, ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

COPD inhaled triple therapy (BDP/FF/G) improved symptoms, lung function, adherence, and QOL in patients previously treated with inhaled dual therapy.

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Learn how to rapidly identify, manage, and prevent drowning injuries using updated evidence-based approaches from prehospital care to ICU management.

FDA Clears New Lung DrugThe US Food and Drug Administration has approved Jascayd (nerandomilast) tablets for adults with ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...